Shots:
- The P-III VOYAGE trial involves assessing Dupixent (100/200mg, q2w, based on weight) + SOC asthma therapy in 408 children aged 6-11yrs. with uncontrolled mod. to-sev. asthma with evidence of type 2 inflammation
- Results: improvement in asthma control @24wks. (1.34/ 1.33 vs 0.88/ 1.00); improvement in ACQ-7-IA; reduction in mean FeNO levels to below the threshold for type 2 inflammation; improvement in overall asthma symptom control
- The safety and efficacy of Dupixent in the pediatric population have not been fully evaluated by any regulatory authority. The company is expecting the FDA’s decision in this population by Oct 21, 2021
Click here to read full press release/ article | Ref: Regeneron | Image: Clinical Trials Arena
The post Regeneron and Sanofi Present Results of Dupixent (dupilumab) in P-III VOYAGE Study for Asthma at ATS 2021 first appeared on PharmaShots.
